Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Feb 13. doi: 10.1007/s00415-019-09208-0. [Epub ahead of print]

PMID:
30758665
2.

Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Jakimovski D, Ramanathan M, Weinstock-Guttman B, Bergsland N, Ramasamay DP, Carl E, Dwyer MG, Zivadinov R.

Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667. [Epub ahead of print]

PMID:
30755085
3.

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.

Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.

J Comp Eff Res. 2019 Feb 13. doi: 10.2217/cer-2018-0135. [Epub ahead of print]

4.

Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.

Jakimovski D, Benedict RH, Marr K, Gandhi S, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608. [Epub ahead of print]

PMID:
30625030
5.

Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis.

Zivadinov R, Bergsland N, Dwyer MG.

Quant Imaging Med Surg. 2018 Nov;8(10):979-983. doi: 10.21037/qims.2018.11.01. No abstract available.

6.

Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?

Ziliotto N, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Ramanathan M, Marchetti G, Bernardi F.

Thromb Haemost. 2019 Jan;119(1):175-178. doi: 10.1055/s-0038-1676346. Epub 2018 Dec 31.

PMID:
30597511
7.

Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration.

Laganá MM, Mendozzi L, Pelizzari L, Bergsland NP, Pugnetti L, Cecconi P, Baselli G, Clerici M, Nemni R, Baglio F.

Curr Neurovasc Res. 2018;15(4):282-291. doi: 10.2174/1567202616666181123164235.

PMID:
30468125
8.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

PMID:
30467212
9.

Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F.

Neuroimage. 2019 Feb 1;186:308-320. doi: 10.1016/j.neuroimage.2018.11.011. Epub 2018 Nov 14.

PMID:
30445148
10.

Plasma levels of soluble NCAM in multiple sclerosis.

Ziliotto N, Zivadinov R, Jakimovski D, Baroni M, Tisato V, Secchiero P, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Bernardi F, Ramanathan M, Marchetti G.

J Neurol Sci. 2019 Jan 15;396:36-41. doi: 10.1016/j.jns.2018.10.023. Epub 2018 Oct 28.

PMID:
30412901
11.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
12.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
13.

Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Jakimovski D, Topolski M, Kimura K, Marr K, Gandhi S, Ramasamy DP, Bergsland N, Hagemeier J, Weinstock-Guttman B, Zivadinov R.

Clin Auton Res. 2018 Aug 17. doi: 10.1007/s10286-018-0555-6. [Epub ahead of print]

PMID:
30120624
14.

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Eur J Neurol. 2019 Jan;26(1):87-e8. doi: 10.1111/ene.13769. Epub 2018 Sep 3.

PMID:
30103277
15.

Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage.

Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS.

J Head Trauma Rehabil. 2018 Sep/Oct;33(5):E24-E32. doi: 10.1097/HTR.0000000000000422.

PMID:
30080799
16.

Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis.

Pelizzari L, Jakimovski D, Laganà MM, Bergsland N, Hagemeier J, Baselli G, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1703-1709. doi: 10.3174/ajnr.A5738. Epub 2018 Jul 26.

PMID:
30049718
17.

Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zamboni P, Marchetti G, Zivadinov R, Ramanathan M.

Mult Scler Relat Disord. 2018 Oct;25:37-42. doi: 10.1016/j.msard.2018.07.009. Epub 2018 Jul 7.

PMID:
30031282
18.

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F.

Radiology. 2018 Nov;289(2):487-496. doi: 10.1148/radiol.2018180136. Epub 2018 Jul 17.

PMID:
30015589
19.

Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.

Lin F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, Vaughn C, Gandhi S, Jakimovski D, Hulst HE, Benedict RH, Bergsland N, Fuchs T, Dwyer MG.

Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218. [Epub ahead of print]

PMID:
30004291
20.

Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study.

Fuchs TA, Carolus K, Benedict RHB, Bergsland N, Ramasamy D, Jakimovski D, Weinstock-Guttman B, Kuceyeski A, Zivadinov R, Dwyer MG.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1480-1486. doi: 10.3174/ajnr.A5720. Epub 2018 Jul 5.

PMID:
29976833
21.

Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study.

Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

Hum Brain Mapp. 2018 Oct;39(10):4007-4017. doi: 10.1002/hbm.24227. Epub 2018 Jun 19.

PMID:
29923266
22.

Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2018 Sep;28(5):490-495. doi: 10.1111/jon.12527. Epub 2018 Jun 1.

PMID:
29856910
23.

Hemostasis biomarkers in multiple sclerosis.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Marchetti G, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Schweser F, Zamboni P, Ramanathan M, Zivadinov R.

Eur J Neurol. 2018 Sep;25(9):1169-1176. doi: 10.1111/ene.13681. Epub 2018 Jun 26.

PMID:
29758118
24.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
25.

Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.

Tavazzi E, Bergsland N, Cattaneo D, Gervasoni E, Laganà MM, Dipasquale O, Grosso C, Saibene FL, Baglio F, Rovaris M.

J Neurol. 2018 Jun;265(6):1393-1401. doi: 10.1007/s00415-018-8859-y. Epub 2018 Apr 7.

PMID:
29627940
26.

Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.

Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 May 15;388:175-181. doi: 10.1016/j.jns.2018.03.028. Epub 2018 Mar 17.

PMID:
29627017
27.

Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.

Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10.

PMID:
29571854
28.

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R.

Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018.

29.

The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.

Uher T, Krasensky J, Sobisek L, Seidl Z, Bergsland N, Dwyer MG, Kubala Havrdova E, Zivadinov R, Horakova D, Vaneckova M.

J Neuroimaging. 2018 May;28(3):328-337. doi: 10.1111/jon.12505. Epub 2018 Feb 27.

PMID:
29485230
30.

Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.

Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D.

AJNR Am J Neuroradiol. 2018 Apr;39(4):642-647. doi: 10.3174/ajnr.A5541. Epub 2018 Feb 8.

PMID:
29439125
31.

Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease.

Guttuso T Jr, Bergsland N, Hagemeier J, Lichter DG, Pasternak O, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Feb 1. doi: 10.3174/ajnr.A5545. [Epub ahead of print]

PMID:
29419398
32.

Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study.

Zivadinov R, Hagemeier J, Bergsland N, Tavazzi E, Weinstock-Guttman B.

Eur J Neurol. 2018 Mar;25(3):584-e36. doi: 10.1111/ene.13562.

PMID:
29316038
33.

Neck Vessel Cross-Sectional Area Measured with MRI: Scan-Rescan Reproducibility for Longitudinal Evaluations.

Pelizzari L, Laganà MM, Jakimovski D, Bergsland N, Hagemeier J, Baselli G, Zivadinov R.

J Neuroimaging. 2018 Jan;28(1):48-56. doi: 10.1111/jon.12488. Epub 2017 Dec 4.

34.

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.

Hagemeier J, Ramanathan M, Schweser F, Dwyer MG, Lin F, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Neuroimage Clin. 2017 Nov 8;17:530-540. doi: 10.1016/j.nicl.2017.11.003. eCollection 2018.

35.

Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.

Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D; MS-MRIUS Study Group.

AJNR Am J Neuroradiol. 2018 Feb;39(2):289-295. doi: 10.3174/ajnr.A5442. Epub 2017 Nov 23.

36.

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.

Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Nov 5;17:444-451. doi: 10.1016/j.nicl.2017.11.002. eCollection 2018.

37.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739. [Epub ahead of print]

PMID:
29143562
38.

Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.

Schweser F, Raffaini Duarte Martins AL, Hagemeier J, Lin F, Hanspach J, Weinstock-Guttman B, Hametner S, Bergsland N, Dwyer MG, Zivadinov R.

Neuroimage. 2018 Feb 15;167:438-452. doi: 10.1016/j.neuroimage.2017.10.063. Epub 2017 Oct 31.

39.

Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy.

Groppo E, Baglio F, Cattaneo D, Tavazzi E, Bergsland N, Di Tella S, Parelli R, Carpinella I, Grosso C, Capra R, Rovaris M.

Front Neurol. 2017 Sep 19;8:491. doi: 10.3389/fneur.2017.00491. eCollection 2017.

40.

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.

Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Jun 19;15:769-779. doi: 10.1016/j.nicl.2017.06.022. eCollection 2017.

41.

Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease.

Woodward MR, Dwyer MG, Bergsland N, Hagemeier J, Zivadinov R, Benedict RH, Szigeti K.

Psychiatry Res Neuroimaging. 2017 Aug 30;266:90-95. doi: 10.1016/j.pscychresns.2017.06.004. Epub 2017 Jun 9.

42.

Serum iron concentration is associated with subcortical deep gray matter iron levels in multiple sclerosis patients.

Bergsland N, Agostini S, Laganà MM, Mancuso R, Mendozzi L, Tavazzi E, Cecconi P, Clerici M, Baglio F.

Neuroreport. 2017 Aug 2;28(11):645-648. doi: 10.1097/WNR.0000000000000804.

PMID:
28509815
43.

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R.

J Neuroimaging. 2017 Nov;27(6):620-629. doi: 10.1111/jon.12445. Epub 2017 May 2.

PMID:
28464417
44.

Heart Rate Modification of Cardiac Output Following Cardiac Surgery: The Importance of Cardiac Time Intervals.

Tavazzi G, Kontogeorgis A, Guarracino F, Bergsland N, Martinez-Naharro A, Pepper J, Price S.

Crit Care Med. 2017 Aug;45(8):e782-e788. doi: 10.1097/CCM.0000000000002410.

PMID:
28437372
45.

Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain.

Hagemeier J, Zivadinov R, Dwyer MG, Polak P, Bergsland N, Weinstock-Guttman B, Zalis J, Deistung A, Reichenbach JR, Schweser F.

Neuroimage Clin. 2017 Apr 13;18:1007-1016. doi: 10.1016/j.nicl.2017.04.008. eCollection 2018.

46.

Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlas- and voxel-based analyses (VBA).

Hanspach J, Dwyer MG, Bergsland NP, Feng X, Hagemeier J, Bertolino N, Polak P, Reichenbach JR, Zivadinov R, Schweser F.

J Magn Reson Imaging. 2017 Nov;46(5):1474-1484. doi: 10.1002/jmri.25671. Epub 2017 Mar 6.

47.

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M.

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

48.

An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study.

Zivadinov R, Khan N, Medin J, Christoffersen P, Price J, Korn JR, Bonzani I, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B.

J Neuroimaging. 2017 May;27(3):339-347. doi: 10.1111/jon.12411. Epub 2016 Dec 5.

49.

Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.

Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B.

Mult Scler. 2017 Sep;23(10):1336-1345. doi: 10.1177/1352458516678083. Epub 2016 Nov 4.

PMID:
27811339
50.

Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis.

Roy S, Schwartz CE, Duberstein P, Dwyer MG, Zivadinov R, Bergsland N, Powell V, Weinstock-Guttman B, Benedict RH.

J Int Neuropsychol Soc. 2016 Oct;22(9):920-927. Epub 2016 May 6.

PMID:
27151620

Supplemental Content

Loading ...
Support Center